Inverness Medical Innovations Announces Third Quarter 20...(s ended September 30 2009 on an adjusted...),Health

Date:10/27/2009

s ended September 30, 2009, on an adjusted cash basis, are dilutive shares consisting of 1,428,000 common stock equivalent shares from the potential exercise of stock options and warrants. Also included were potential dilutive shares consisting of 3,422,000 common stock equivalent shares from the potential conversion of convertible debt securities, 10,985,000 common stock equivalent shares from the potential conversion of Series B convertible preferred stock and 346,000 common stock equivalents from the potential settlement of a portion of the deferred purchase price consideration related to the ACON Second Territory Business. The diluted net income per common share calculation for the nine months ended September 30, 2009, on an adjusted cash basis, includes the add back of interest expense related to the convertible debt of $2.1 million, the add back of $17.1 million of preferred stock dividends related to the Series B convertible preferred stock and the add back of interest expense related to the ACON Second Territory Business of $0.2 million resulting in net income available to common stockholders of $184.2 million for the nine months ended September 30, 2009.

(n) Included in the weighted average diluted common shares for the calculation of net income per common share for the nine months ended September 30, 2008, on an adjusted cash basis, are dilutive shares consisting of 2,349,000 common stock equivalent shares from the potential exercise of stock options and warrants and potential dilutive shares consisting of 3,411,000 common stock equivalent shares from the potential conversion of convertible debt securities. The net income per diluted share calculation for the nine months ended September 30, 2008, on an adjusted cash basis, includes the add back of interest expense related to the convertible debt of $2.1 million resulting in net income available to common stockholders of $108.6 million. Potential dilutive shares consisting of 5,479,000 common s
'/>"/>

SOURCE Inverness Medical Innovations, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Related medicine technology :

1. Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimers Disease
2. Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General
3. Inverness Medical Innovations Receives USDA Licensure of the BinaxNOW(R) Avian Influenza Virus Type A Antigen Test Kit
4. Inverness Medical Innovations to Present at CIBC World Markets 18th Annual Healthcare Conference on November 7, 2007
5. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
6. Medical Food Reduces Medical Costs and Use of Anticonvulsant Medication When Treating Diabetic Neuropathy, According to HealthCore Study Presented at ISPOR
7. Reportlinker Adds Medical Devices & Equipment in India (2009)
8. ATS Medical Announces Third Quarter 2009 Earnings Release Date and Conference Call
9. Rcadia Medical Imaging Wins 2009 AuntMinnie.com Best New Radiology Vendor Award
10. Cardio Vascular Medical Device Sends Update to Shareholders
11. Symmetry Medical Updates Full Year 2009 Financial Guidance